Sanara MedTech Reports Q1 Profitability, 19% Revenue Growth, Reaffirms Full-Year Guidance

summarizeSummary

Sanara MedTech reported a return to net profitability and strong 19% revenue growth in Q1 2026, validating its strategic focus on the surgical market and reaffirming full-year guidance.

check_boxKey Events

• Return to Profitability

  Sanara MedTech reported net income of $0.4 million ($0.04 per diluted share) from continuing operations in Q1 2026, a significant improvement from a net loss of $0.6 million ($0.07 per diluted share) in Q1 2025.

• Strong Revenue Growth

  Net revenue increased 19% year-over-year to $27.8 million, driven by increased sales of soft tissue repair products.

• Improved Operating Performance

  Gross profit margin expanded to 93%, and Adjusted EBITDA increased 58% to $4.3 million.

• Guidance Reaffirmed

  The company reaffirmed its full-year 2026 net revenue guidance of $116 million to $121 million, representing 13% to 17% growth, and provided Q2 2026 revenue guidance of $28.5 million to $29.5 million.

auto_awesomeAnalysis

This filing is highly important because it demonstrates the successful execution of Sanara MedTech's strategic realignment. The company achieved GAAP net profitability from continuing operations in Q1 2026, a significant turnaround from a loss in the prior year. This, coupled with strong 19% revenue growth and improved operating metrics, validates the company's focus on the surgical market. Reaffirming full-year guidance after such a strong quarter provides confidence in the company's future performance and financial stability.